AMB-001 is under clinical development by Ambicion and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AMB-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMB-001 is under development for the treatment of relapsed or advanced solid tumors. The therapy constitutes RK-163 pulsed human autologous CD14-positive cells. It is administered by intravenous route.
For a complete picture of AMB-001’s drug-specific PTSR and LoA scores, buy the report here.